14 Melanoma Marches down, 7 to go!
19 March 2018
The weather varied, with high temps in Canberra, Bunbury, Manly and Newcastle, while Adelaide and Bunbury bore the brunt of wind and some rain. Needless to say, all six Marches were overwhelming successes.
Bendigo, with a population of less than 100,000 people, has raised a whopping $16,000 for Melanoma Institute Australia. This is incredible and the feedback has been amazing, with the committee working tirelessly to put on what was a great event.
It was a beautiful morning in Newcastle, there was a breeze and it was very scenic down near Nobby’s beach. While emotions ran high, the sense of community was undeniable, with everyone supporting one another and all Marching for the same cause. With over 300 people attending the March, Newcastle has broken the $30,000 fundraising tally mark, which is a huge achievement.
Manly had a change of location and added an additional challenge. Participants tackled stand-up-paddle boarding on a 3km loop, while the majority Marched collectively, following the Fairlight walking path. With nearly 500 people registering at Manly, the event was a huge success.
Canberra reached big numbers with over 300 participants attending the March this year. Our country’s capital always produces a great atmosphere for Marchers to show support to those who have been affected by melanoma.
Bunbury, a small town in Western Australia held Melanoma March, and, for the first time ever included a 10km optional running track. In partnership with melanomaWA, Melanoma March Bunbury contributed to raising life-saved funds for melanoma research. Thank you to the committee and to melanomaWA for their continued support.
Thank you to all participants, committee members, supporters and to all. Melanoma March is a time to remember, honour and support those who have had or have melanoma. But there is still work to be done. We still have 7 Marches in various states to go, so let’s not lose momentum. It is time to end melanoma.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.